Exhibit 99.1


Contact:  David Gryska                                Brian P. Gill
          Senior Vice President and                   Vice President,
          Chief Financial Officer                     Corporate Communications
          Celgene Corporation                         Celgene Corporation
          (908) 673-9059                              (908) 673-9530

          Breanna Burkart/Anna Sussman
          Directors, Investor Relations and Corporate Communications
          Pharmion Corporation
          (720) 564-9150

         GERMAN FEDERAL CARTEL OFFICE CLEARS CELGENE TO ACQUIRE PHARMION

SUMMIT, NJ - (January 28, 2008) - Celgene Corporation (NASDAQ: CELG) and
Pharmion Corporation (NASDAQ: PHRM) announced that the Bundeskartellamt,
Germany's Federal Cartel Office in charge of reviewing the antitrust aspects of
mergers and acquisitions, has cleared Celgene's pending acquisition of Pharmion
Corporation.

As previously announced on January 3, 2008, the 30-day waiting period under the
Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, expired
without the United States Federal Trade Commission requesting additional
information.

About Celgene

Celgene Corporation, headquartered in Summit, New Jersey is an integrated global
pharmaceutical company engaged primarily in the discovery, development and
commercialization of innovative therapies for the treatment of cancer and
inflammatory diseases through gene and protein regulation. For more information,
please visit the Company's website at www.celgene.com.

About Pharmion

Pharmion Corporation is a leading global oncology company focused on acquiring,
developing and commercializing innovative products for the treatment of
hematology and oncology patients in the U.S., Europe and additional
international markets. Pharmion has a number of products on the market including
the world's first approved epigenetic drug, Vidaza(R), a DNA demethylating
agent. For additional information about Pharmion, please visit the company's
website at http://www.pharmion.com.

This release contains forward-looking statements which are subject to known and
unknown risks, delays, uncertainties and other factors not under the Companies
control, which may cause actual results, performance or achievements of the
Companies to be materially different from the results, performance or other
expectations expressed or implied by these forward-looking statements. These
factors include results of current or pending research and development
activities, actions by the FDA and other regulatory authorities, and other
factors described in





the Companies filings with the Securities and Exchange Commission such as our
10K, 10Q and 8K reports.


                                      # # #